StreetAlpha.app
Home › Stocks › CBIO

Crescent Biopharma, Inc. (CBIO)

$13.04
▼ −3.41%
LAST CLOSE · NOV 17

Crescent Biopharma develops cancer treatments, including antibody and antibody drug conjugate candidates still in clinical trials. It last closed at $13.04 on Nov 17, down 3.41% on the day. The average 12-month price target from 3 analysts is $33.00 (+153.1% from the last close), with a high of $40.00 and a low of $27.00. Analyst consensus is Strong Buy, based on the latest ratings from 3 firms (3 buy, 0 hold, 0 sell). Over the past 90 days StreetAlpha recorded 1 whale options trade in CBIO, 100% of them bullish and 0% bearish.

AI Auto Pilots
Is CBIO in one of our four AI portfolios? Sign in free to see

Key Stats

Last 12 months
Results
Revenue
$15.0M
Net income
−$178.2M
−1188.3% margin
Free cash flow
−$82.4M
−549.5% margin
Operating margin
−1216.6%
−$182.5M operating income
Valuation
Market cap
$507.2M
38.9M shares
P/E
–
Price to sales
33.8
Market cap over revenue
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$289.4M
At Sep 30
Shareholder equity
$274.3M
Shares outstanding
38.9M
At Nov 11
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: $1.2M$1.2MFY2021FY2022: $75K$75KFY2022FY2023: $10K$10KFY2023FY2025: $10.8M$10.8MFY2025

From CBIO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 12). Last 12 months adds up the four latest quarters.

Last report
Nov 12
2026 · next date not on the calendar yet
Consensus EPS forecast
—
 
Year-ago EPS
—
Not on file
Options-implied move
—
 
Analyst consensus
Strong Buy
Based on 3 analyst ratings (90 days)
Loading…

Analyst Ratings & Price Targets

Analyst Ratings →
Consensus · 90 days
Strong Buy
3firms
3 Buy0 Hold0 Sell
Each firm's latest rating on CBIO in the past 90 days
Average 12-month target
$33.00
▲ 153.1% upside

Based on 3 analysts who set a price target on CBIO in the past 90 days. The average target is $33.00, with a high of $40.00 and a low of $27.00, compared with the last close of $13.04.

Low $27.00Avg $33.00High $40.00
Blue marker: last close $13.04
Highest target$40.00
Average target$33.00
Lowest target$27.00
Latest rating changes
Piper SandlerMaintained
Nov 13Buy$32
HC Wainwright & Co.Target raised
Nov 13Buy$36 → $40
HC Wainwright & Co.Reiterated
Oct 19Buy$36
HC Wainwright & Co.Upgrade
Oct 6Buy$36
WedbushReiterated
Aug 27Buy$27
DateFirmActionRatingPrice target
Nov 13Piper SandlerMaintainedBuy$32
Nov 13HC Wainwright & Co.Target raisedBuy$36 → $40
Oct 19HC Wainwright & Co.ReiteratedBuy$36
Oct 6HC Wainwright & Co.UpgradeBuy$36
Aug 27WedbushReiteratedBuy$27
Loading…

Technical Analysis

CBIO · as of the Nov 17 close · updated after every close
Downtrend

The stock is 3% below its 20 day and 11% below its 50 day average. It is 23% below its 200 day average, so the longer trend is down. Momentum is neutral (RSI 44). The nearest support is the Pivot S1 at $12.72, and the nearest resistance the Pivot at $13.21.

Short trendBearish
Long trendBearish
MomentumNeutral
StretchNormal
VolatilityNormal, 8.6%/day
Key levels
$27.4152 week high+110.2%
$15.99200 day average+22.6%
$15.67100 day average+20.2%
$14.5150 day average+11.3%
$13.81Swing high (Oct 21)+5.9%
$13.53Pivot R1+3.8%
$13.4920 day average+3.5%
$13.21Pivot+1.3%
$13.04Last close
$12.72Pivot S1−2.5%
$12.68Swing low (Nov 2)−2.8%
$8.7252 week low−33.1%
Indicators
RSI (14)43.88Middle of its rangeNeutral
MACD-0.11Above its signal lineBullish
Stochastic32.6Middle of its rangeNeutral
ADX (14)11.6No clear trend
Williams %R-87.0Oversold below −80, overbought above −20Oversold
CCI (20)-54.4Oversold below −100, overbought above 100Neutral
Rate of change−0.1%Change over 10 sessionsBearish
ATR (14)$1.13Typical daily range, 8.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for CBIO

What happened before

See how CBIO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.

November seasonalityHow CBIO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

Seasonality

How CBIO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2014.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Total alerts
1
Bullish
1
100%
Bearish
0
0%
Date span
Sep 3 – Sep 3
Loading…

See today’s whale options flow across the market →

CBIO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲81 buying vs 27 selling
  • ▲Held by funds +28.4 pts
  • ▲Funds holding +24
  • ●Superinvestors: 2 added, 2 cut
  • ●Put/call not meaningful
Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding10682+29.3%
In funds' top 10330.0%
Held by funds104.5%76.1%+28.4 pts
New / increased37 / 4432 / 17+65.3%
Reduced / sold out13 / 1415 / 13−3.6%
Put/call ratio0.00––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See CBIO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

AI Auto Pilots

Paper trading

StreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether CBIO is in one of them and how their past CBIO trades turned out.

CBIO in the AI portfolios
Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered CBIO in an article yet. Here's the latest on the wider market.

About Crescent Biopharma

Crescent Biopharma is a biotechnology company based in Waltham, Massachusetts, that develops treatments for cancer. Its lead candidate, CR-001, is an antibody designed to bind two proteins, PD-1 and VEGF, that affect how tumors grow and how the immune system responds. The company is also developing antibody drug conjugates, which are designed to deliver a toxin directly to cancer cells. Its candidates are still in clinical trials and are not yet approved for sale.

Headquarters
Waltham, MA